Charles A. Peloquin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charles A. Peloquin has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
David E. Nix
College of Pharmacy and Medicine, University of Arizona, Tucson, Arizona
4 shared publications- Min Zhu
Regeneron Pharmaceuticals, Inc. Tarrytown New York USA
4 shared publications Shaun E. Berning
Division of Infectious Diseases, Department of Medicine , Denver, Colorado
4 shared publicationsJames M. Childs
Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado
3 shared publicationsAmy E. Bulpitt
Department of Medicine, National Jewish Medical and Research Center, University of Colorado, Denver, Colorado
2 shared publicationsGeorge S. Jaresko
School of Pharmacy, University of Southern California School of Medicine, Los Angeles, California
2 shared publications
Latest Publications
- 4 February 2009
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (3) , 381-401
Tuberculosis pharmacotherapy: strategies to optimize patient care
Introduction: The treatment of tuberculosis (TB) is a mature discipline, with more than 60 years of clinical experience accrued across the globe. The requisite Multi-drug treatment of drug-suscepti...
- 4 February 2009
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (3) , 381-401
Tuberculosis pharmacotherapy: strategies to optimize patient care
Introduction: The treatment of tuberculosis (TB) is a mature discipline, with more than 60 years of clinical experience accrued across the globe. The requisite Multi-drug treatment of drug-suscepti...
- Open Access
- 1 March 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (3) , 852-857
Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis
The objective of this study was to determine the population pharmacokinetic parameters of levofloxacin, gatifloxacin, and moxifloxacin following multiple oral doses. Twenty-nine patients with tuberculosis at the University Hospital in Vitória, Brazil, participated. Subjects received multiple doses of one drug (levofloxacin, 1,000 mg daily, or gatifloxacin or moxifloxacin, 400 mg daily) as part of a 7-day study of early bactericidal activity. Serum samples were collected over 24 h after the fifth dose and assayed using validated high-performance liquid chromatography assays. Concentration-time data were analyzed using noncompartmental, compartmental, and population methods. The three drugs were well tolerated. Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 μg/ml; gatifloxacin, 4.75 μg/ml; moxifloxacin, 6.13 μg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h). A one-compartment model, with or without weight as a covariate, adequately described the data. Postmodeling simulations using median population parameter estimates closely approximated the median values from the original data. Area under the concentration-time curve/MIC ratios for free drug were high. All three quinolones showed favorable pharmacokinetic and pharmacodynamic indices, with the most favorable results in this population being seen with levofloxacin at the comparative doses used.
- 1 March 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (3) , 852-857
Open AccessPopulation Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis
The objective of this study was to determine the population pharmacokinetic parameters of levofloxacin, gatifloxacin, and moxifloxacin following multiple oral doses. Twenty-nine patients with tuberculosis at the University Hospital in Vitória, Brazil, participated. Subjects received multiple doses of one drug (levofloxacin, 1,000 mg daily, or gatifloxacin or moxifloxacin, 400 mg daily) as part of a 7-day study of early bactericidal activity. Serum samples were collected over 24 h after the fifth dose and assayed using validated high-performance liquid chromatography assays. Concentration-time data were analyzed using noncompartmental, compartmental, and population methods. The three drugs were well tolerated. Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 μg/ml; gatifloxacin, 4.75 μg/ml; moxifloxacin, 6.13 μg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h). A one-compartment model, with or without weight as a covariate, adequately described the data. Postmodeling simulations using median population parameter estimates closely approximated the median values from the original data. Area under the concentration-time curve/MIC ratios for free drug were high. All three quinolones showed favorable pharmacokinetic and pharmacodynamic indices, with the most favorable results in this population being seen with levofloxacin at the comparative doses used.
- Open Access
- 15 August 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (4) , 521
Stability of Antituberculosis Drugs Mixed in Food
TO THE EDITOR— Tablet or capsule administration is difficult in young children or patients with dysphagia, and most antituberculosis drugs are not available in liquid formulations. Pharmacies can prepare extemporaneous dosage forms, but stability data are limited for such preparations [1]. Therefore, we tested the stability of tuberculosis drugs in common foods that might be palatable for children.
- 15 August 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (4) , 521
Open AccessStability of Antituberculosis Drugs Mixed in Food
TO THE EDITOR— Tablet or capsule administration is difficult in young children or patients with dysphagia, and most antituberculosis drugs are not available in liquid formulations. Pharmacies can prepare extemporaneous dosage forms, but stability data are limited for such preparations [1]. Therefore, we tested the stability of tuberculosis drugs in common foods that might be palatable for children.
- Open Access
- 15 August 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (4) , 461-469
Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana
Background. We conducted a pharmacokinetic study of antimycobacterial drugs involving a cohort of patients with pulmonary tuberculosis (TB) in Gaboro
- 15 August 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (4) , 461-469
Open AccessSerum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana
Background. We conducted a pharmacokinetic study of antimycobacterial drugs involving a cohort of patients with pulmonary tuberculosis (TB) in Gaboro
- Open Access
- 1 June 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (11) , 1538-1544
Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases
Aminoglycoside use is limited by ototoxicity and nephrotoxicity. This study compared the incidences of toxicities associated with 2 recommended dosin
- 1 June 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (11) , 1538-1544
Open AccessAminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases
Aminoglycoside use is limited by ototoxicity and nephrotoxicity. This study compared the incidences of toxicities associated with 2 recommended dosin
- 1 June 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (6) , 686-695
Population Pharmacokinetic Modeling of Pyrazinamide in Children and Adults with Tuberculosis
Study Objective. To determine population pharmacokinetic parameters of pyrazinamide after multiple oral doses given to children and adults with tuberculosis.Design. Prospective, multiple‐dose population pharmacokinetic study.Setting. Five hospitals in the United States.Patients. Sixty‐seven adults and 23 children with active tuberculosis.Intervention. The 90 patients received multiple oral doses of pyrazinamide as part of their treatment, based on the best clinical judgment of the attending physicians and in keeping with standard clinical practices at each institution. The patients also received other antituberculosis drugs empirically or based on in vitro susceptibility data.Measurements and Main Results. Serum samples were collected over 12 hours after dosing and were assayed with a validated gas chromatography assay with mass selective detection. Concentration‐time data were analyzed by using population methods. Pyrazinamide concentrations increased linearly with increasing oral doses (185–3550 mg). Median maximum serum concentration values were 41.0 μg/ml with daily dosing and 66.1 μg/ml with larger, twice‐weekly dosing. Incomplete (18%) or delayed (30%) absorption was more common in children than in adults (1% for each). Pharmacokinetic parameters of pyrazinamide were independent of human immunodeficiency virus status and patient demographics, except for body weight. Population elimination half‐life values in pediatric and adult patients were 3.5 and 6.0 hours, respectively. Median volume of distribution (L/kg) was 32% larger in children, and median clearance (L/hr/kg) was 106% larger in children, with a resultant median half‐life 43% shorter in children.Conclusion. Pyrazinamide concentrations and most pharmacokinetic parameters were comparable to those previously published. Apparent half‐life was somewhat shorter than that in previous reports. Compared with adults, absorption of pyrazinamide in children appeared more likely to be incomplete or delayed.
- 1 June 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (6) , 686-695
Population Pharmacokinetic Modeling of Pyrazinamide in Children and Adults with Tuberculosis
Study Objective. To determine population pharmacokinetic parameters of pyrazinamide after multiple oral doses given to children and adults with tuberculosis.Design. Prospective, multiple‐dose population pharmacokinetic study.Setting. Five hospitals in the United States.Patients. Sixty‐seven adults and 23 children with active tuberculosis.Intervention. The 90 patients received multiple oral doses of pyrazinamide as part of their treatment, based on the best clinical judgment of the attending physicians and in keeping with standard clinical practices at each institution. The patients also received other antituberculosis drugs empirically or based on in vitro susceptibility data.Measurements and Main Results. Serum samples were collected over 12 hours after dosing and were assayed with a validated gas chromatography assay with mass selective detection. Concentration‐time data were analyzed by using population methods. Pyrazinamide concentrations increased linearly with increasing oral doses (185–3550 mg). Median maximum serum concentration values were 41.0 μg/ml with daily dosing and 66.1 μg/ml with larger, twice‐weekly dosing. Incomplete (18%) or delayed (30%) absorption was more common in children than in adults (1% for each). Pharmacokinetic parameters of pyrazinamide were independent of human immunodeficiency virus status and patient demographics, except for body weight. Population elimination half‐life values in pediatric and adult patients were 3.5 and 6.0 hours, respectively. Median volume of distribution (L/kg) was 32% larger in children, and median clearance (L/hr/kg) was 106% larger in children, with a resultant median half‐life 43% shorter in children.Conclusion. Pyrazinamide concentrations and most pharmacokinetic parameters were comparable to those previously published. Apparent half‐life was somewhat shorter than that in previous reports. Compared with adults, absorption of pyrazinamide in children appeared more likely to be incomplete or delayed.
- 1 June 2002
- Published by Elsevier in Tuberculosis
- Vol. 82 (2-3) , 91-96
Population pharmacokinetics of ethionamide in patients with tuberculosis
- 1 June 2002
- Published by Elsevier in Tuberculosis
- Vol. 82 (2-3) , 91-96
Population pharmacokinetics of ethionamide in patients with tuberculosis
- 1 January 2002
- Published by Springer Nature in Drugs
- Vol. 62 (15) , 2169-2183
Therapeutic Drug Monitoring in the Treatment of Tuberculosis
Therapeutic drug monitoring (TDM) is a standard clinical technique used for many disease states, including many infectious diseases. As for these other conditions, the use of TDM in the setting of...
- 1 January 2002
- Published by Springer Nature in Drugs
- Vol. 62 (15) , 2169-2183
Therapeutic Drug Monitoring in the Treatment of Tuberculosis
Therapeutic drug monitoring (TDM) is a standard clinical technique used for many disease states, including many infectious diseases. As for these other conditions, the use of TDM in the setting of...
- 1 December 2001
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 953b (1) , 157-164
Pharmacological Issues in the Treatment of Tuberculosis
Abstract: A thorough review of the clinical trial data combined with new in vitro experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.
- 1 December 2001
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 953b (1) , 157-164
Pharmacological Issues in the Treatment of Tuberculosis
Abstract: A thorough review of the clinical trial data combined with new in vitro experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.